Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins
about
Extracellular matrix macromolecules: potential tools and targets in cancer gene therapyLumican is overexpressed in lung adenocarcinoma pleural effusionsRelation of dietary inorganic arsenic to serum matrix metalloproteinase-9 (MMP-9) at different threshold concentrations of tap water arsenicTranscriptional profiling provides insights into metronomic cyclophosphamide-activated, innate immune-dependent regression of brain tumor xenograftsLumican overexpression exacerbates lipopolysaccharide-induced renal injury in miceLumican Inhibits SNAIL-Induced Melanoma Cell Migration Specifically by Blocking MMP-14 Activity.The transcriptome and miRNome profiling of glioblastoma tissues and peritumoral regions highlights molecular pathways shared by tumors and surrounding areas and reveals differences between short-term and long-term survivors.Lumican effectively regulates the estrogen receptors-associated functional properties of breast cancer cells, expression of matrix effectors and epithelial-to-mesenchymal transition.Proteoglycans: Potential Agents in Mammographic Density and the Associated Breast Cancer Risk.Implementation of infrared and Raman modalities for glycosaminoglycan characterization in complex systems.Dynamics of internalization and recycling of the prometastatic membrane type 4 matrix metalloproteinase (MT4-MMP) in breast cancer cells.The significance of lumican expression in ovarian cancer drug-resistant cell lines.Keratan Sulphate, a complex Glycosaminoglycan with Unique Functional Capability.Expression of small leucine-rich extracellular matrix proteoglycans biglycan and lumican reveals oral lichen planus malignant potential.Strategies to Target Matrix Metalloproteinases as Therapeutic Approach in Cancer.Decreased elastic fibers and increased proteoglycans in the ligamentum flavum of patients with lumbar spinal canal stenosis.
P2860
Q26996081-2B82C1FB-6D7C-4FA7-A431-E2C1378EC604Q28261832-0F221534-29F5-46A5-AD8B-634D07579161Q28397998-DEA2C14E-CD98-473F-BF1A-80EBA4F3D07BQ35624661-8AB1C343-9E27-4617-B072-8E7FE5D8ABF8Q35919735-33DA46C4-8C66-4E05-8442-B5C77935C5B5Q35941197-188A50D6-FC93-4C07-B092-2DDC9EEA303FQ36356011-C3D3EF90-8A49-47DC-81A4-8723FE3D7BA3Q37717157-92CE2CD3-8666-4A81-8BC6-D620E3A3C7A7Q38616484-C8DB059D-6194-42E5-A40E-2155D260AB3BQ39032574-94D7BCBD-E1C7-4967-92BE-766966D870C8Q40216249-4C58BA89-356F-4A5D-B137-DE2B66A69928Q47132524-555C5B6B-FD2F-4BD5-A5D9-F0CCE2A91494Q47860795-F2A4E637-DD9E-46E8-AD44-39F39558A2E2Q47988612-77BE706B-2D0F-440C-8ECF-8F78E445EFDCQ50109651-10EFC06D-5DA4-48C1-AF07-27D9CB7E7D19Q50206302-4CA911B3-1003-4FD6-BEB7-BCDCFF471C35
P2860
Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Lumican effects in the control ...... talloproteinases and integrins
@ast
Lumican effects in the control ...... talloproteinases and integrins
@en
Lumican effects in the control ...... talloproteinases and integrins
@nl
type
label
Lumican effects in the control ...... talloproteinases and integrins
@ast
Lumican effects in the control ...... talloproteinases and integrins
@en
Lumican effects in the control ...... talloproteinases and integrins
@nl
prefLabel
Lumican effects in the control ...... talloproteinases and integrins
@ast
Lumican effects in the control ...... talloproteinases and integrins
@en
Lumican effects in the control ...... talloproteinases and integrins
@nl
P2093
P2860
P356
P1433
P1476
Lumican effects in the control ...... talloproteinases and integrins
@en
P2093
François-Xavier Maquart
Stéphane Brézillon
Yanusz Wegrowski
P2860
P304
P356
10.1111/FEBS.12210
P407
P577
2013-03-18T00:00:00Z